carvacryl acetate profile

Carvacryl acetate is an ester derived from carvacrol, a naturally occurring monoterpenoid phenol found in essential oils of plants such as oregano and thyme. It is synthesized by esterification of carvacrol with acetic anhydride. Carvacryl acetate exhibits antimicrobial activity against various bacteria and fungi. It is also reported to have antioxidant and anti-inflammatory properties. Research on carvacryl acetate focuses on its potential applications in food preservation, cosmetics, and pharmaceuticals. It is studied for its ability to control food spoilage, enhance the shelf life of products, and provide antimicrobial protection. Additionally, its anti-inflammatory effects make it a promising candidate for the development of topical treatments for skin conditions.'

carvacryl acetate: a derivative of carvacrol that reduces nociceptive and inflammatory response in mice; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	80792
CHEBI ID	179898
SCHEMBL ID	247416
MeSH ID	M0591595

Synonym
acetic acid, carvacryl-
CHEBI:179898
5-isopropyl-2-methylphenol acetate
(2-methyl-5-propan-2-ylphenyl) acetate
4395-82-8
6380-28-5
nsc6601
nsc-6601
carvacrol acetate
acetic acid, carvacryl-,
carvacryl acetate
einecs 228-963-4
5-isopropyl-o-tolyl acetate
unii-2a2br75b36
ai3-03429
2a2br75b36 ,
phenol, 2-methyl-5-(1-methylethyl)-, acetate
nsc 6601
AKOS006227942
SCHEMBL247416
OXZSUQJHKQOGOK-UHFFFAOYSA-N
5-isopropyl-2-methylphenyl acetate #
mfcd00270428
2-methyl-5-(propan-2-yl)phenyl acetate
acetic acid 5-isopropyl-2-methyl-phenyl ester
Q27254462
DTXSID40863777

Excerpt	Reference	Relevance
"Carvacryl acetate (CA) is a semisynthetic monoterpenic ester obtained from essential oils, and it exerts an antioxidation effect. "	( Carvacryl acetate, a semisynthetic monoterpenic ester obtained from essential oils, provides neuroprotection against cerebral ischemia reperfusion-induced oxidative stress injury via the Nrf2 signalling pathway. Ai, LY; Bei, Y; Lin, PY; Ma, QZ; Qin, DX; Song, Y; Wang, LB, 2020)	3.44
"Carvacryl acetate is a promising anti-inflammatory and antioxidant agent, a fact confirmed through observations of its interactions with TRPA1 in CPT-11-induced intestinal mucositis in mice."	( Carvacryl acetate, a novel semisynthetic monoterpene ester, binds to the TRPA1 receptor and is effective in attenuating irinotecan-induced intestinal mucositis in mice. Alvarenga, EM; Araújo, AR; Brito, GAC; de Araújo, S; Iles, B; Júnior, JLP; Medeiros, JVR; Pacífico, DM; Sousa, DP; Sousa, NA; Souza, EP, 2017)	3.34

Excerpt	Reference	Relevance
"Pretreatment with carvacryl acetate also decreased the number of acetic acid-induced writhing, increased the latency time of the animals on the hot plate and decreased paw licking time in the formalin, capsaicin and glutamate tests."	( Carvacryl acetate, a derivative of carvacrol, reduces nociceptive and inflammatory response in mice. Barbosa, AL; Brito, CF; Carvalho, NS; Damasceno, SR; Freitas, RM; Medeiros, JV; Oliveira, FR; Silva, IS; Silva, RO; Sousa, DP; Sousa, FB, 2014)	2.17

Excerpt	Reference	Relevance
" The LD10 and LD50 of CA were 566."	( Comparative efficacy and toxic effects of carvacryl acetate and carvacrol on sheep gastrointestinal nematodes and mice. Andre, WP; Bevilaqua, CM; Cavalcante, GS; de Freitas, RM; de Melo, JV; de Morais, SM; de Paula, HC; dos Santos, JM; Macedo, IT; Ribeiro, WL, 2016)	0.7
" nCVA showed LD50 of 2,609 mg/kg."	( Anthelmintic activity of nanoencapsulated carvacryl acetate against gastrointestinal nematodes of sheep and its toxicity in rodents. Abreu, FOMDS; Alves, APNN; André, WPP; Araújo Filho, JV; Bevilaqua, CML; Cavalcante, GS; Monteiro, JP; Morais, SM; Oliveira, LMB; Paiva Junior, JR; Ribeiro, WLC; Santos, JMLD; Silva, INGD, 2020)	0.82

Class	Description
monoterpenoid	Any terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (54.55)	24.3611
2020's	5 (45.45)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
praziquantel azinox: Russian drug	2.6	1	isoquinolines
carvacrol carvacrol : A phenol that is a natural monoterpene derivative of cymene. An inhibitor of bacterial growth, it is used as a food additive. Potent activator of the human ion channels transient receptor potential V3 (TRPV3) and A1 (TRPA1).	7.13	1	botanical anti-fungal agent; p-menthane monoterpenoid; phenols	agrochemical; antimicrobial agent; flavouring agent; TRPA1 channel agonist; volatile oil component
lucanthone hydrochloride Schistosomicides: Agents that act systemically to kill adult schistosomes.	2.31	1
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.15	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
irinotecan [no description available]	7.15	1	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.1	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
chitosan [no description available]	7.31	1

Condition	Relationship Strength	Studies
Schistosoma mansoni Infection [description not available]	7.31	1
Schistosomiasis mansoni Schistosomiasis caused by Schistosoma mansoni. It is endemic in Africa, the Middle East, South America, and the Caribbean and affects mainly the bowel, spleen, and liver.	2.31	1
Cerebral Ischemia [description not available]	7.25	1
Injury, Ischemia-Reperfusion [description not available]	2.25	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.25	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.25	1
Infections, Nematode [description not available]	2.9	3
Ovine Diseases [description not available]	2.9	3
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	2.15	1
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	2.15	1
Mucositis An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).	7.15	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.1	1
Anasarca [description not available]	2.1	1
Diseases of Immune System [description not available]	2.1	1
Innate Inflammatory Response [description not available]	2.1	1
Leukocyte Disorders Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells.	2.1	1
Ache [description not available]	2.1	1
Primary Peritonitis [description not available]	2.1	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.1	1
Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.	2.1	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.1	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.1	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	2.1	1
Absence Seizure [description not available]	2.11	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	7.11	1

carvacryl acetate

Description

Cross-References

Synonyms (27)

Research Excerpts

Overview

Treatment

Toxicity

Drug Classes (1)

Research

Studies (11)

Market Indicators

Research Demand Index: 19.77

Study Types